orforglipron vs tirzepatide Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Orforglipron, an Oral Small-Molecule GLP-1

And what should patients with OCD know before starting treatment

Participants in the highest quartile of total logs per month experienced 2.0% (95% CI: 2.4, 1.6) greater weight loss, 0.65 kg/m 2 (95% CI: 0.79, 0.52) greater BMI reduction, and 2.9 mmHg (95% CI: 5.0, 0.9) greater reduction in systolic blood pressure, compared to those in the lowest quartile

Can I take a multivitamin instead of a separate Vitamin D supplement

The primary effect on fertility is indirect and generally positive, resulting from weight reduction and metabolic optimization rather than direct reproductive toxicity

This low dose is continued for at least four weeks and then gradually increased to make sure that the body is closely monitored for any negative side effects

These conditions significantly increase the chance of developing cardiovascular disease, stroke, and Type 2 diabetes